A Phase 2 Open Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Dose Levels of Subcutaneoulsy Administered ELX-02 in Patients with Cystic Fibrosis with at Least One G542X Allele.
- Wilson, John (Primary Chief Investigator (PCI))
- Burr, Lucy D. (Chief Investigator (CI))
- Morton, Judith M. (Chief Investigator (CI))
- Visser, Simone K. (Chief Investigator (CI))
Project: Research